Most Recent
A director of an energy company who was kicked off the board for missing too many meetings has filed an appeal of a ruling dismissing his case over delays in complying with court requests after his lawyer from Maddocks withdrew from the case due to late payments.
Dairy giant Parmalat has come up short in its attempt to block competitor The a2 Milk Company from registering a trade mark in Australia for a logo featuring the words "A2/A2 Genetics Verification".
The Australian Competition and Consumer Commission has brought legal action against Bupa alleging the aged care provider charged thousands of residents for promised extra services it did not provide.
Generic drug maker Sandoz has secured a retroactive licence to manufacture a cheaper version of top-selling antidepressant Lexapro, the drug at the heart of a long-running patent infringement battle with pharmaceutical giant Lundbeck.
ANZ has reached an in-principle settlement in two class actions alleging it breached its responsible lending obligations by providing loans to purchasers of 7-Eleven franchises that were not financially viable.
Racing Victoria has dragged fantasy sports gambling company PlayUp to court for allegedly infringing its 'Best Bets' trade marks.
The Australian Competition and Consumer Commission and the US Federal Bureau of Investigation have signed an agreement under which the agencies will work more closely to target cartels and other anti-competitive behaviour.
Wealth manager IOOF has dismissed a shareholder class action lawsuit related to allegations of misconduct aired at the Banking Royal Commission, calling it "speculative and unfounded".
Australia's largest intellectual property services firm IPH will maintain its dominance after winning a takeover battle for Xenith IP, a deal that will create a formidable IP services giant with over 1,000 employees across Asia Pacific.
A judge has denied Mylan's bid to temporarily block Sun Pharma and Cipla from making generic versions of anti-cholesterol drug Lipidil while it appeals a ruling invalidating several claims of its patents for the drug, citing the "difficulty, complexity and uncertainty" in assessing compensation under an undertaking as to damages in pharmaceutical patent proceedings.